RIKEN-NKT(NKT Cell Target Therapy)

A dendritic cell vaccine that specifically stimulates the activation of NKT cells in the body using the NKT cell activation technology of RIKEN Immune-Regenerative Medicine, a bio-venture company originating from RIKEN.

NKT cells are characterized as NK cells with T-cell receptors. However, unlike ordinary T cells, which recognize antigens presented on histocompatibility antigens on the cell surface, it is known that CD1d molecules on antigen-presenting cells bind glycolipids and activate NKT cells. The unique feature of NKT cell therapy is that when these cells are highly activated, they powerfully induce cellular immunity and activate T cells, NK cells, and other lymphocytes that have the ability to attack tumors. lymphocytes that are capable of attacking tumors, such as T cells and NK cells.